Mazars USA adds Wayne Pryor as head of healthcare transaction services
Mazars USA has added Wayne Pryor as a partner and head of the healthcare transaction services group. He remains based in Nashville.
Pryor brings more than 30 years of experience in the healthcare industry, with a focus on transaction services. He has delivered financial diligence services on the buy- and sell-side for 400+ transactions ranging in value from $1 million to $10+ billion, and covering every subsector of the industry.
Pryor will support Mazars’ healthcare industry clients with deep expertise in assessing financial risk in transactions, as well as advising on post-transaction and integration.
He joins from BKD CPAs & Advisors, where he spent the last two years as a managing director in the transaction advisory healthcare practice. Before that, he spent 14 years at Big Four firm EY, where he was an executive director in the transaction advisory healthcare practice.
Prior to entering consulting, Pryor held several industry leadership positions, including director of planning and analysis/decision support systems at the Mayo Clinic and finance and accounting manager at Baptist St. Vincent’s Health System.
He holds a BA in accounting from Western State College and is a CPA in Arizona, Florida, and Tennessee.
Robert Kastenschmidt, national consulting leader at Mazars USA, said, "In this time of unprecedented change for healthcare, Wayne's experience guiding clients with strategic transactions will be of significant benefit and value. His background in building solid foundations for healthcare organizations will be invaluable in addressing the pandemic and post-pandemic environments."
The US life sciences and healthcare sector in September saw the highest monthly volume of transactions in the year-to-date, according to a Q3 deals report from Epstein Becker Green, KPMG, and FocalPoint Partners. Deal volume jumped to 201 in September – up from 166 in August and just shy of the January high-point of 213 deals. The recent upswing follows several months of depressed activity due to the pandemic.
Envision Pharma Group earlier this month announced its acquisition of Two Labs, an Ohio-based provider of pharmaceutical commercialization advisory services.
